阿里索尔A24-乙酸盐通过通过AMPK/mTOR途径抑制活性氧物种和炎症反应来改善骨关节炎的进展
Guosong Xu1, Zhensen He1, Yinping Liu1
1Department of Orthopedics, The First Hospital of Putian City, Putian, China.
Immunity, inflammation and disease
|May 30, 2023
概括
阿里索尔A24-酸盐 (ALA-24A) 通过减少炎症和氧化应激来保护骨关节炎. 这种化合物显示出作为治疗膝关节疾病的潜在治疗方法的希望.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 生物医学工程 生物医学工程
背景情况:
- 骨关节炎是一种退行性关节疾病,其特征是软骨的分解和炎症.
- 阿里索尔A24-酸盐 (ALA-24A) 具有已知的抗氧化和抗炎性质.
- 在骨关节炎中,ALA-24A的治疗潜力和分子机制仍然未被探索.
研究的目的:
- 研究ALA-24A对骨关节炎的保护作用.
- 阐明ALA-24A在骨关节炎中的作用背后的分子机制.
主要方法:
- 利用IL-1β诱导的冠状细胞和MIA诱导的老鼠关节炎模型.
- 评估了细胞活力,细胞外基质 (ECM) 降解,炎症和氧化应激.
- 采用了CCK-8测定,西部斑点,ELISA,DCFH-DA探针,以及他的病理学分析.
主要成果:
- 在老鼠中,ALA-24A减轻了IL-1β诱导的胆细胞损伤,并保护了对软骨的降解.
- 通过ALA-24A调节的ECM合成和降解标记物 (Aggrecan, 原II, ADAMTS5, MMP13).
- 通过激活AMPK/mTOR通路,ALA-24A可以减少氧化应激 (ROS,MDA) 和炎症 (NO,PGE2,TNF-α,IL-6).
结论:
- ALA-24A 显示出对骨关节炎的显著保护作用.
- 抑制氧化应激和炎症是ALA-24A的关键机制.
- 阿拉-24A代表了骨关节炎治疗的潜在治疗候选者.
相关概念视频
01:20The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
01:22PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
181
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
181